Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2012

01-05-2012 | Original paper

Estrogen-related genes and their contribution to racial differences in breast cancer risk

Authors: Kerryn W. Reding, Chu Chen, Kimberly Lowe, David R. Doody, Christopher S. Carlson, Christina T. Chen, John Houck, Linda K. Weiss, Polly A. Marchbanks, Leslie Bernstein, Robert Spirtas, Jill A. McDonald, Brian L. Strom, Ronald T. Burkman, Michael S. Simon, Jonathan M. Liff, Janet R. Daling, Kathleen E. Malone

Published in: Cancer Causes & Control | Issue 5/2012

Login to get access

Abstract

Racial differences in breast cancer risk, including the risks of hormone receptor subtypes of breast cancer, have been previously reported. We evaluated whether variation in genes related to estrogen metabolism (COMT, CYP1A1, CYP1B1, CYP17A1, CYP19A1, ESR1, GSTM1, GSTP1, GSTT1, HSD17B1, SULT1A1, and UGT1A1) contributes to breast cancer risk and/or racial differences in risk within the CARE study, a multi-centered, population-based case–control study of breast cancer. Genetic variation was assessed as single nucleotide polymorphisms (SNPs), haplotypes, and SNP–hormone therapy (HT) interactions within a subset of 1,644 cases and 1,451 controls, including 949 Black women (493 cases and 456 controls), sampled from the CARE study population. No appreciable associations with breast cancer risk were detected for single SNPs or haplotypes in women overall. We detected SNP–HT interactions in women overall within CYP1B1 (rs1800440; p het = 0.003) and within CYP17A1 (rs743572; p het = 0.009) in which never users of HT were at a decreased risk of breast cancer, while ever users were at a non-significant increased risk. When investigated among racial groups, we detected evidence of an SNP–HT interaction with CYP1B1 in White women (p value = 0.02) and with CYP17A1 in Black women (p value = 0.04). This analysis suggests that HT use may modify the effect of variation in estrogen-related genes on breast cancer risk, which may affect Black and White women to a different extent.
Appendix
Available only for authorised users
Literature
1.
Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 66:8327–8330PubMedCrossRef
2.
Morris GJ, Mitchell EP (2008) Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc 100:698–702PubMed
3.
Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11:601–607PubMed
4.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef
5.
Jones BA, Kasl SV, Howe CL et al (2004) African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101:1293–1301PubMedCrossRef
6.
Joe AK, Hibshoosh H (2005) African-American/White differences in breast carcinoma. Cancer 104:661–662PubMedCrossRef
7.
Simon MS, Korczak JF, Yee CL et al (2006) Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women’s Contraceptive and Reproductive Experiences Study. J Clin Oncol 24:2498–2504PubMedCrossRef
8.
Chlebowski RT, Chen Z, Anderson GL et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439–448PubMedCrossRef
9.
Huo D, Ikpatt F, Khramtsov A et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521PubMedCrossRef
10.
Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281:2091–2097PubMedCrossRef
11.
Millikan RC, Newman B, Tse CK et al. (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123–139
12.
Hall P, Ploner A, Bjohle J et al (2006) Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med 4:16PubMed
13.
Biglia N, Sgro L, Defabiani E et al (2005) The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 31:467–472PubMedCrossRef
14.
Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103:470–477PubMedCrossRef
15.
Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113:1521–1526PubMedCrossRef
16.
Brett KM, Madans JH (1997) Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 145:536–545PubMedCrossRef
17.
Setiawan VW, Haiman CA, Stanczyk FZ, Le ML, Henderson BE (2006) Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 15:1849–1855PubMedCrossRef
18.
Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE (2005) Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 14:2147–2153PubMedCrossRef
19.
Haiman CA, Pike MC, Bernstein L et al (2002) Ethnic differences in ovulatory function in nulliparous women. Br J Cancer 86:367–371PubMedCrossRef
20.
Randolph JF Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ (2004) Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 89:1555–1561PubMedCrossRef
21.
Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF Jr (2006) Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med 119:S16–S22PubMedCrossRef
22.
Beckmann L, Husing A, Setiawan VW et al (2011) Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab 96:E360–E367PubMedCrossRef
23.
Friedenreich CM (2001) Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10:15–32PubMedCrossRef
24.
Kato I, Cichon M, Yee CL, Land S, Korczak JF (2009) African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol 33:24–30PubMedCrossRef
25.
Rebbeck TR, Troxel AB, Walker AH et al (2007) Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev 16:444–450PubMedCrossRef
26.
Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ (1995) A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55:3757–3758PubMed
27.
Van Emburgh BO, Hu JJ, Levine EA et al (2008) Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 19:1311–1321PubMed
28.
Bryc K, Auton A, Nelson MR et al (2010) Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci U S A 107:786–791PubMedCrossRef
29.
Fejerman L, Haiman CA, Reich D et al (2009) An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev 18:3110–3117PubMedCrossRef
30.
Tishkoff SA, Reed FA, Friedlaender FR et al (2009) The genetic structure and history of Africans and African Americans. Science 324:1035–1044PubMedCrossRef
31.
Sexton KR, Franzini L, Day RS, Brewster A, Vernon SW, Bondy ML (2011) A review of body size and breast cancer risk in Hispanic and African American women. Cancer 117:5271–5281PubMedCrossRef
32.
Marchbanks PA, McDonald JA, Wilson HG et al (2002) The NICHD Women’s Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 12:213–221PubMedCrossRef
33.
Rothman KJ (1986) Modern epidemiology, 1st edn. Little, Brown and Co, Boston
34.
Greenland S, Thomas DC (1982) On the need for the rare disease assumption in case–control studies. Am J Epidemiol 116:547–553PubMed
35.
Miettinen O (1976) Estimability and estimation in case-referent studies. Am J Epidemiol 103:226–235PubMed
36.
Lavigne JA, Helzlsouer KJ, Huang HY et al (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57:5493–5497PubMed
37.
Hayashi S, Watanabe J, Nakachi K, Kawajiri K (1991) Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 110:407–411PubMed
38.
Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C (2007) Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 16:481–489PubMedCrossRef
39.
Crofts F, Cosma GN, Currie D, Taioli E, Toniolo P, Garte SJ (1993) A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 14:1729–1731PubMedCrossRef
40.
Sakoda LC, Blackston C, Doherty JA et al (2008) Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev 17:1066–1073PubMedCrossRef
41.
Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL (1998) A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8:43–48PubMedCrossRef
42.
Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H (1996) Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 11:306–311PubMedCrossRef
43.
Sano M, Inoue S, Hosoi T et al (1995) Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun 217:378–383PubMedCrossRef
44.
Kristensen VN, Andersen TI, Erikstein B et al (1998) Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 8:441–447CrossRef
45.
Fryer AA, Zhao L, Alldersea J, Pearson WR, Strange RC (1993) Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A, B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochem J 295(Pt 1):313–315PubMed
46.
Kosoy R, Nassir R, Tian C et al (2009) Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat 30:69–78PubMedCrossRef
47.
Falush D, Stephens M, Pritchard JK (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164:1567–1587PubMed
48.
Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155:945–959PubMed
49.
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300
50.
Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812–3814PubMedCrossRef
51.
Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCrossRef
52.
National Center for Biotechnology Information (2009) Entrez SNP website
53.
Wacholder S (1991) Practical considerations in choosing between the case-cohort and nested case–control designs. Epidemiol Res 2:155–158CrossRef
54.
Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA (2010) Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 121:281–292PubMedCrossRef
55.
Rebbeck TR, Troxel AB, Shatalova EG et al (2007) Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:1318–1320PubMedCrossRef
56.
Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF (1998) Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 58:65–70PubMed
57.
Bailey LR, Roodi N, Dupont WD, Parl FF (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58:5038–5041PubMed
58.
Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR (2005) Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14:1998–2003PubMedCrossRef
59.
Liu J, Papasian C, Deng HW (2007) Incorporating single-locus tests into haplotype cladistic analysis in case–control studies. PLoS Genet 3:e46PubMedCrossRef
60.
The International HapMap Consortium (2003) The International HapMap Project Nature 426:789–796
61.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Ris (2010) Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. Breast Cancer Res Treat 120:737–744CrossRef
62.
Chen Y, Gammon MD, Teitelbaum SL et al (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29:766–771PubMedCrossRef
63.
Justenhoven C, Hamann U, Schubert F et al (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137–149PubMedCrossRef
64.
Reding KW, Weiss NS, Chen C et al (2009) Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18:1461–1467PubMedCrossRef
65.
Diergaarde B, Potter JD, Jupe ER et al (2008) Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 17:1751–1759PubMedCrossRef
66.
Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440–3444PubMed
67.
Goth-Goldstein R, Erdmann CA, Russell M (2003) Cytochrome P4501B1 expression in normal breast tissue, 23 ed. p. 275
68.
Murray GI, Taylor MC, McFadyen MC et al (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026–3031PubMed
69.
Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D (2000) Estrogens as endogenous genotoxic agents–DNA adducts and mutations. J Natl Cancer Inst Monogr 27:75–93
70.
Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67–73
71.
de Jong MM, Nolte IM, te Meerman GJ et al (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39:225–242PubMedCrossRef
72.
Weiss LK, Burkman RT, Cushing-Haugen KL et al (2002) Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 100:1148–1158PubMedCrossRef
73.
Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL (1990) Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol 4:1972–1979PubMedCrossRef
74.
Ma H, Wang Y, Sullivan-Halley J et al (2009) Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev 18:2214–2220PubMedCrossRef
Metadata
Title
Estrogen-related genes and their contribution to racial differences in breast cancer risk
Authors
Kerryn W. Reding
Chu Chen
Kimberly Lowe
David R. Doody
Christopher S. Carlson
Christina T. Chen
John Houck
Linda K. Weiss
Polly A. Marchbanks
Leslie Bernstein
Robert Spirtas
Jill A. McDonald
Brian L. Strom
Ronald T. Burkman
Michael S. Simon
Jonathan M. Liff
Janet R. Daling
Kathleen E. Malone
Publication date
01-05-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-9925-x

Other articles of this Issue 5/2012

Cancer Causes & Control 5/2012 Go to the issue

Original paper

Family history of malignant and benign thyroid diseases and risk of thyroid cancer: a population-based case–control study in New Caledonia

Original paper

Obesity and the incidence of skin cancer in US Caucasians

Brief report

Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies

Original paper

Associations of intakes of fat, dietary fiber, soy isoflavones, and alcohol with levels of sex hormones and prolactin in premenopausal Japanese women

Original paper

Obesity and colorectal cancer screening among black and white adults

Original paper

Baseline human papillomavirus infection, high vaginal parity, and their interaction on cervical cancer risks after a follow-up of more than 10 years
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits